Skip to main content

Development of a TB vaccine in Africa

Objective

Despite the millions of deaths from tuberculosis each year and the threat of increased drug resistance, tuberculosis vaccine development has been hugely under-resourced. We set out here to evaluate the safety and immunogenicity of new subunit Constructs in Africa, a continent in desperate need of an effective tuberculosis vaccine. We shall employ two attenuated poxvirus vectors, modified virus Ankara and the FP9 adios strain that both have a marked capacity to boost pre-existing T cell responses, each expressing the secreted mycobacterium antigen, Ag85A. We shall initially test the vaccines individually at different doses and then in heterogonous prime-boost regimes to identify an immunisation regime that works well both in non-infected individuals and also in those already infected by M tuberculosis, a post-exposure vaccination group. In parallel we shall measure the incidence of tuberculosis infection and disease in various high-risk cohorts in this region to identify a group in whom tuberculosis subunit vaccines may in future be tested efficiently.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
Address

Dakar
Senegal

Participants (3)

MEDICAL RESEARCH COUNCIL
The Gambia
Address
Atlantic Boulevard 273
20 Fajara
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Address
John Radcliffe Hospital - Oxfordshire 5802
OX3 9DU Oxford/headington
UNIVERSITE CHEIKH ANTA DIOP DE DAKAR
Senegal
Address
Avenue Pasteur
30 Dakar